선천성 부신과형성증(CAH) : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(주요 32개 시장)(2025-2035년)

Global Congenital Adrenal Hyperplasia (CAH) Market Outlook

Thelansis's "Global Congenital Adrenal Hyperplasia (CAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Adrenal Hyperplasia treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Congenital Adrenal Hyperplasia (CAH) Overview

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive adrenal steroidogenesis disorders, with 21-hydroxylase deficiency caused by CYP21A2 mutations accounting for over 90% of cases, disrupting cortisol and aldosterone biosynthesis while redirecting steroid precursors toward androgen excess. Disease severity spans classic salt-wasting CAH presenting neonatally with adrenal crisis, hyponatraemia, hyperkalaemia, and virilisation, through simple virilising and non-classic forms manifesting with premature adrenarche, hirsutism, menstrual irregularity, and subfertility. Newborn screening via 17-hydroxyprogesterone measurement enables early diagnosis, confirmed by CYP21A2 genotyping and adrenal steroid profiling. Glucocorticoid replacement suppresses ACTH-driven androgen excess while restoring deficient cortisol; mineralocorticoid replacement with fludrocortisone addresses salt-wasting. Balancing glucocorticoid dosing remains clinically challenging, as under-replacement perpetuates androgen excess while over-replacement risks iatrogenic Cushing syndrome and growth suppression. Crinecerfont, an approved CRF1 receptor antagonist, represents a paradigm-shifting adjunctive therapy reducing androgen excess and enabling glucocorticoid dose reduction in eligible patients, while tildacerfont and other agents remain in active development. Adrenal crisis prevention through sick-day rules and emergency hydrocortisone is critical. Prognosis is favourable with adherence; endocrinological surveillance, psychological support, and multidisciplinary patient-centred care are integral to optimising lifelong outcomes.

Key Highlights

• In France, prevalent CAH cases are projected to increase from approximately 74,390 in 2025 to 76,704 by 2035.
• CAH remains a rare endocrine disorder characterized by impaired cortisol synthesis and hormonal imbalance.
• Lifelong disease management is required to prevent adrenal crises and optimize growth and development outcomes.
• Increasing newborn screening programs are supporting earlier diagnosis and intervention.
• Novel therapeutic approaches aim to improve hormonal control while reducing steroid-related complications.

Market Overview

• The Italy CAH market is projected to grow from approximately $60 MN to $170 MN by 2035.
• Market growth is supported by:
• Increasing utilization of improved hormone replacement therapies
• Growing awareness and earlier disease diagnosis
• Market expansion is driven by long-term treatment requirements and emerging targeted therapies.
• Future growth will depend on next-generation endocrine therapies and disease-modifying approaches.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Crinetics Pharmaceuticals Inc.
• Neurocrine Biosciences
• Spruce Biosciences
• H. Lundbeck A/S
• Neurocrine UK Limited
• Adrenas Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)